|
With a population of more than one billion, India provides one of the largest patient population bases in the world. A major benefit is that most patients visit hospitals without prior treatment, meaning they have a clear presentation of the disease under research. Patients come from all socio-economic strata, trust in their doctor’s advice and have less formal contacts with investigators, so they are likely to be good follow up prospects for long-term studies.
Another advantage of India is the regulatory environment, which is sensitive and encouraging toward industry needs for performing international clinical trials. Most of the local ethics committees are currently in compliance with ICH-GCP and local regulatory requirements in terms of composition and function of the EC. The Indian regulatory authorities tend to be vigilant, active and have a straightforward approach.
Our full-service office in India is staffed by experts in patient recruitment and with wide ranging therapeutic experience in key areas including oncology, psychiatry, cardiovascular, neurology and infections. |
